Oncolytic Virus Combination Regimens to Overcome Immune Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic virus therapies face challenges such as immune clearance, limited tumor selectivity, and viral tropism, leading to modest clinical success rates and the need for improved delivery and immune activation.
Innovation Solution
A combination therapy using distinct serotypes of oncolytic viruses, administered sequentially or simultaneously, to overcome immune-mediated resistance and enhance tumor targeting, leveraging diverse antigenic profiles and tumor-killing effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a single oncolytic virus strain is used for cancer treatment, then the treatment is simple to administer, but the host immune system rapidly recognizes and neutralizes the virus, limiting therapeutic efficacy
Solution Approach 1:
The patent combines multiple oncolytic virus strains with different antigenic profiles into a single therapeutic regimen. This merging approach maintains ease of administration while overcoming immune neutralization, as the diverse viral antigens prevent the host immune system from rapidly recognizing and eliminating all viral particles simultaneously, thereby sustaining therapeutic efficacy.
Solution Approach 2:
The invention creates a composite virotherapeutic product comprising multiple distinct oncolytic virus strains. This composite approach leverages the diverse antigenic properties of different virus strains to evade immune detection while maintaining simple administration protocols, resolving the contradiction between operational simplicity and therapeutic reliability.
2Reliability
If oncolytic viruses are administered to overcome immune resistance, then therapeutic efficacy improves, but the complexity of treatment regimens increases
Solution Approach 1:
The patent merges multiple oncolytic virus strains into a single combined therapeutic administration. This approach enhances therapeutic efficacy by diversifying antigenic profiles to overcome immune resistance while maintaining relative simplicity in the treatment regimen, as the viruses are administered together rather than requiring complex sequential protocols.
3Adaptability or versatility
If a single serotype of oncolytic virus is used, then the viral tropism is well-defined, but the tumor selectivity is limited to specific cancer types
Solution Approach 1:
The patent employs multiple oncolytic virus strains with different serotypes, each possessing distinct tropism characteristics. This multi-functional approach enables the treatment to target a broader spectrum of tumor types while maintaining reliable viral tropism for each specific cancer type, as each virus strain can selectively infect its target tissue based on its inherent tropism properties.
Solution Approach 2:
The invention creates a composite virotherapeutic formulation comprising multiple virus strains with complementary tropism profiles. This composite approach broadens tumor selectivity across different cancer types while preserving the reliable, type-specific viral tropism of each individual strain, allowing tailored targeting of different tumor tissues.
Data Source
AI summary
A combination therapeutic strategy employs multiple oncolytic viruses (OVs), grouped and administered based on their virological properties, tumor selectivity, and distinct antigen profiles, to treat malignant tumors. Representative groupings may include members of flaviviruses, each contributing distinct immune modulation and the same modes of tumor cell killing. A predefined treatment schedule involves sequential or concurrent administration of antigenically diverse OVs in multiple cycles, reducing cross-neutralization and sustaining cytolytic pressure on tumors. A pre-characterized OV panel, comprising members from a virus family, RNA and DNA viruses, both wild-type and genetically engineered, serves as a flexible resource for customizing treatment regimens by tumor type, immune landscape, and therapeutic goals. This platform establishes a rational framework for combination OV therapy with improved durability, safety, and clinical effectiveness.